Vericel (NASDAQ:VCEL) Insider Sean Flynn Sells 15,000 Shares

Vericel Corporation (NASDAQ:VCEL) insider Sean Flynn sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $45.64, for a total value of $684,600.00. Following the transaction, the insider directly owned 1,647 shares in the company, valued at $75,169.08. The trade was a 90.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Vericel Trading Down 1.3%

VCEL opened at $44.49 on Wednesday. The stock’s fifty day simple moving average is $36.51 and its 200 day simple moving average is $35.90. Vericel Corporation has a 1-year low of $28.95 and a 1-year high of $46.62. The stock has a market cap of $2.27 billion, a PE ratio of 105.93 and a beta of 1.12.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. Vericel had a net margin of 7.35% and a return on equity of 6.41%. The firm had revenue of $68.43 million during the quarter, compared to analysts’ expectations of $63.68 million. During the same period in the previous year, the business posted ($0.23) earnings per share. The company’s revenue for the quarter was up 30.1% compared to the same quarter last year. Equities analysts forecast that Vericel Corporation will post 0.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on VCEL shares. Wall Street Zen lowered shares of Vericel from a “buy” rating to a “hold” rating in a research note on Sunday, June 14th. Weiss Ratings upgraded shares of Vericel from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 16th. Leerink Partners reaffirmed an “outperform” rating and issued a $46.00 target price on shares of Vericel in a research report on Tuesday, March 10th. HC Wainwright reiterated a “buy” rating and set a $64.00 target price on shares of Vericel in a research note on Friday, May 8th. Finally, Truist Financial lowered their target price on Vericel from $48.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, April 15th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $52.50.

Hedge Funds Weigh In On Vericel

A number of hedge funds have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new stake in Vericel in the 4th quarter worth about $27,000. Huntington National Bank increased its holdings in shares of Vericel by 51.3% during the third quarter. Huntington National Bank now owns 805 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 273 shares during the period. Quarry LP bought a new position in shares of Vericel during the fourth quarter worth approximately $31,000. Farther Finance Advisors LLC raised its position in shares of Vericel by 116.5% in the fourth quarter. Farther Finance Advisors LLC now owns 970 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 522 shares in the last quarter. Finally, Truvestments Capital LLC raised its position in shares of Vericel by 175.4% in the fourth quarter. Truvestments Capital LLC now owns 1,534 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 977 shares in the last quarter.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.